Journal Mobile Options
Table of Contents
Vol. 61, No. 4, 2001
Issue release date: November 2001
Oncology 2001;61:299–305
(DOI:10.1159/000055337)

STn and Prognosis in Breast Cancer

Leivonen M. · Nordling S. · Lundin J. · von Boguslawski K. · Haglund C.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Sialyl-Tn (STn) is a carbohydrate antigen formed by the premature 2–6 sialylation of N-acetylgalactosamine. It belongs to a family of antigens widely expressed in carcinomas but only to a limited degree in normal tissue. The expression of STn has been associated with prognosis in different tumors. In this immunohistochemical study of 218 patients with invasive stage I–III breast cancer, STn was expressed in 39% of the tumors. High expression of STn correlated with estrogen and progesterone hormone receptor negativity (p = 0.0002 and p = 0.0003, respectively), and marginally with large tumor size (p = 0.04), high S-phase fraction (p = 0.04) and aneuploidy (p = 0.04), but not significantly with node status, grade or age. The patients had a median follow-up of 17 years. The breast-cancer-specific survival rate of patients with STn-negative cancers was higher than that of patients with cancers that expressed STn during the first 5 years of the follow-up (p = 0.013), but the difference between the groups decreased during the long-term follow-up. STn expression seems to be a marker for short-term, but not for long-term breast cancer outcome prediction.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Hakomori S: Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res 1989;52:257–331.
  2. Devine PL, McKenzie IF: Mucins: Structure, function, and associations with malignancy. Bioessays 1992;14:619–625.
  3. Ho SB, Niehans GA, Lyftogt C, Yan PS, Cherwitz DL, Gum ET, Dahiya R, Kim Y: Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:641–651.
  4. Carneiro F, Santos L, David L, Dabelsteen E, Clausen H, Sobrinho-Simoes M: T (Thomsen-Friedenreich) antigen and other simple mucin-type carbohydrate antigens in precursor lesions of gastric carcinoma. Histopathology 1994;24:105–113.
  5. Mandel U, Petersen OW, Sorensen H, Vedtofte P, Hakomori SI, Clausen H, Dabelsteen E: Simple mucin-type carbohydrates in oral stratified squamous and salivary gland epithelia. J Invest Dermatol 1991;97:713–721.
  6. Stenersen TC, Dabelsteen E: Changes in the glycosylation pattern of histo-blood group antigens in benign, premalignant and malignant laryngeal epithelial lesions. APMIS 1992;100(suppl 27):139–148.
  7. Reddish M, Suresh M, Koganty R, Frotier S, Baronic L, Berg A, Longenecker M: Analysis of the role of type 1 core O-glycans in the binding of anti-MUC1 antibodies by cytofluorometry and synthetic peptide/glycopeptide binding inhibition studies. Tumor Biol 1998;19(suppl 1):57–66.
  8. Springer GF: T and Tn, general carcinoma autoantigens. Science 1984;224:1198–1206.
  9. Hirao T, Sakamoto Y, Kamada M, Hamada SI, Aono T: Tn antigen, a marker of potential for metastasis of uterine cervix cancer cells. Cancer 1993;72:154–159.
  10. Itzkowitz SH, Yuan M, Montgomery CK, Kjeldsen T, Takahashi HK, Bigbee WL, Kim YS: Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res 1989;49:197–204.
  11. Reed W, Bryne M, Clausen H, Dabelsteen E, Nesland JM: Simple mucins (T, sialosyl-T, Tn and sialosyl-Tn) are not diagnostic for malignant breast lesions. Anticancer Res 1994;14:609–616.

    External Resources

  12. Kjeldsen T, Clausen H, Hirohashi S: Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2-6a-N-acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Res 1988;48:4361–4367.
  13. Örntoft TF, Harving N, Langkilde NC: O-Linked mucin-type glycoproteins in normal and malignant colon mucosa: Lack of T-antigen expression and accumulation of Tn and sialosyl-Tn antigens in carcinomas. Int J Cancer 1990;45:666–672.
  14. Yonezawa S, Tachikawa T, Shin S, Sato E: Sialosyl-Tn antigen. Its distribution in normal human tissues and expression in adenocarcinomas. Am J Clin Pathol 1992;98:167–174.
  15. Werther JL, Rivera-MacMurray S, Bruckner H, Tatematsu M, Itzkowitz SH: Mucin-associated sialosyl-Tn antigen expression in gastric cancer correlates with an adverse outcome. Br J Cancer 1994;69:613–616.

    External Resources

  16. Werther JL, Tatematsu M, Klein R, Kurihara M, Kumagai K, Llorens P, Neto JG, Bodian C, Pertsemlidis D, Yamachika T, Kitou T, Itzkowitz S: Sialosyl-Tn antigen as a marker of gastric cancer progression: An international study. Int J Cancer 1996;69:193–199.
  17. Victorzon M, Nordling S, Nilsson O, Roberts PJ, Haglund C: Sialyl Tn antigen is an independent predictor of outcome in patients with gastric cancer. Int J Cancer 1966;65:295–300.
  18. Itzkowitz SH, Bloom EJ, Kokal WA, Modin G, Hakomori S, Kim YS: Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 1990;66:1960–1966.
  19. Lundin M, Nordling S, Roberts PJ, Lundin J, Carpelan-Holmström M, von Boguslawsky K, Haglund C: Sialyl Tn is a frequently expressed antigen in colorectal cancer: No correlation with patient prognosis. Oncology 1999;57:70–76.
  20. Cho SH, Sahin A, Hortobagyi GN, Hittelman WN, Dhingra K: Sialyl-Tn antigen expression occurs early during human mammary carcinogenesis and is associated with high nuclear grade and aneuploidy. Cancer Res 1994;54:6302–6305.

    External Resources

  21. Thor A, Ohuchi N, Szpak CA, Johnston WW, Schlom J: Distribution of oncofetal antigen tumor associated glycorprotein-72 defined by monoclonal antibody B72.3. Cancer Res 1986;46:3118–3124.
  22. Contegiacomo A, Alimandi M, Muraro R, Pizzi C, Calderopoli R, DeMarchis L, Sgambato A, Pettinato G, Petrella G, DeFilippo MR, Mariani-Costantini R: Expression of epitopes of the tumour-associated glycoprotein 72 and clinicopathological correlations in mammary carcinomas. Eur J Cancer 1994;30A:813–820.
  23. Soares R, Marinho A, Schmitt F: Expression of sialyl-Tn in breast cancer. Correlation with prognostic parameters. Pathol Res Pract 1996;192:1181–1186.
  24. Miles DW, Happerfield LC, Smith P, Gillibrand R, Bobrow LG, Gregory WM, Rubens RD: Expression of sialyl-Tn predicts the effect of adjuvant chemotherapy in node-positive breast cancer. Br J Cancer 1994;70:1272–1275.
  25. Holmberg LA, Oparin DV, Gooley T, Lilleby K, Bensinger W, Reddish MA, MacLean GD, Longenecker BM, Sandmaier BM: Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine. Bone Marrow Transplant 2000;25:1233–1241.

    External Resources

  26. UICC, TNM Classification of Malignant Tumors, ed 4. Berlin, Springer, 1987.
  27. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991;19:403–410.
  28. Boguslawsky von K: Immunohistochemical detection of progesterone receptors in paraffin sections. APMIS 1994;102:641–646.
  29. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA: Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983;31:1333–1335.
  30. Baisch H, Göhde W, Linden WA: Analysis of PCP data to determine the fraction of cells in various phases of cell cycle. Radiat Environ Biophys 1975;2:31–39.
  31. Blockzjil A, Nilsson K, Nilsson O: Epitope characterization of MUC1 antibodies. Tumor Biol 1998;19(suppl 1)46–56.
  32. Dabelsteen E: Cell surface carbohydrates as prognostic markers in human carcinomas. J Pathol 1996;179:358–369.
  33. Kakeji Y, Maehara Y, Morita M, Matsukuma A, Furusawa M, Takahashi I, Kusumoto T, Ohno S, Sugimachi K: Correlation between sialyl-Tn antigen and lymphatic metastasis in patients with Borrmann type IV gastric carcinoma. Br J Cancer 1995;71:191–195.
  34. Schmitt FC, Figueiredo P, Lacerda M: Simple mucin-type carbohydrate antigens (T, sialosyl-T, Tn and sialosyl-Tn) in breast carcinogenesis. Virchows Arch 1995;427:251–258.
  35. Imada T, Rino Y, Hatori S, Takahashi M, Amano T, Kondo J, Suda T: Sialyl Tn antigen expression is associated with the prognosis of patients with advanced colorectal cancer. Hepatogastroenterology 1999;46:208–214.
  36. Terashima S, Takano Y, Ohori T, Kanno T, Kimura T, Motoki R, Kawaguchi T: Sialyl-Tn antigen as a useful predictor of poor prognosis in patients with advanced stomach cancer. Surg Today 1998;28:682–686.
  37. Ghazizadeh M, Ogawa H, Sasaki Y, Araki T, Aihara K: Mucin carbohydrate antigens (T, Tn, and sialyl-Tn) in human ovarian carcinomas: Relationship with histopathology and prognosis. Hum Pathol 1997;28:960–966.
  38. Kinney AY, Sahin A, Vernon SW, Frankowski RF, Annegers JF, Hortobagyi GN, Buzdar AU, Frye DK, Dhingra K: The prognostic significance of sialyl-Tn antigen in women with breast carcinoma treated with adjuvant chemotherapy. Cancer 1997;80:2240–2249.
  39. Nomoto M, Yonezawa S, Tokunaga M, Kim YS, Sato E: Mucin antigens expression and Ki-67 labeling in breast cancer: The peculiarity in scirrhous carcinoma. Pathol Int 1995;45:233–239.
  40. Ogata S, Koganty R, Reddish M, Longenecker BM, Chen A, Perez C, Itzkowitz SH: Different modes of sialyl-Tn expression during malignant transformation of human colonic mucosa. Glycoconj J 1998;15:29–35.

    External Resources



Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50